Further, in vitro and in vivo evidence suggests that deferoxamine (DFO), an FDA-approved iron chelator under investigation for the treatment of breast cancer [29–33], can enhance uptake of transferrin conjugates by metastatic breast cancer. The gene discussed is TF; the disease is breast carcinoma.